Trial Profile
A Phase II, Open-Label, Efficacy and Safety, Ascending Dose, Pilot Study of be Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2016
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors AstraZeneca; Rigel Pharmaceuticals
- 19 Dec 2013 New trial record